GLP-1 & GIP Updates and Announcements
Let's walk through the Changes you will find in this updated PocketCard
Snap Shot Overview of Changes
- The GLP-1 & GIP Meds PocketCard now includes two distinct versions—one for diabetes and one for weight management with max doses and indications. This side-by-side approach makes it easier to individualize treatment decisions based on a person’s health profile, age, and comorbidities.
- Wegovy 7.2mg High Dose (HD) version was added.
- Oral Wegovy, with 25mg max dose added.
- Rybelsus name updated to Oral Ozempic for 1.5 mg, 4 mg, and 9 mg doses.
- Mounjaro now indicated for peds 10-17 yrs.
Download Your FREE PocketCard Here
Pharmacology Breakdown and More details
Glucagon-like peptide-1 (GLP-1) receptor agonists and GLP/GIP class of medications have seen significant advancements in the past year and 2026 promises to offer even more advancements.
Semaglutide (Wegovy) for Weight Loss Updates – High Dose & Pediatric Approval
The FDA granted accelerated approval in March 2026 for a high-dose (HD) injectable version of Wegovy of 7.2 mg once weekly. Until now, the highest approved dose for Wegovy—the weight loss formulation of the GLP-1 receptor agonist semaglutide—was 2.4 mg weekly.
Many individuals on the maximum 2.4 mg dose eventually reach a weight loss plateau, prompting researchers to explore whether higher dosing could extend weight reduction. Clinical trials demonstrate that increasing the dose to 7.2 mg weekly can lead to additional weight loss of up to ~20–21% from baseline, representing a meaningful advancement for those needing further support.
As expected, gastrointestinal side effects increase with higher doses, particularly, nausea, vomiting, diarrhea and early satiety. As with the other incretin medications, encourage smaller, lower fat meals that are high in nutrients. Remind individuals to keep hydrated and if the nausea persists, they may benefit from anti-nausea medications.
Mounjaro Pediatric Approval Update: Expanding Treatment Options for Youth
A major step forward in pediatric diabetes care is the recent expansion of tirzepatide (Mounjaro) into younger populations. With emerging data and regulatory progress, tirzepatide is being recognized as a potential option for youth with type 2 diabetes and extra weight, offering another powerful new tool to improve metabolic measures for young people with diabetes.
This update reflects a broader shift toward earlier, more effective interventions in youth with diabetes and elevated body weight, aligning with current guidelines that emphasize person-centered, individualized care.
Oral Wegovy Update: Expanding Options with Higher-Dose Therapy
A new advancement in weight management is the availability of Oral Wegovy (oral semaglutide), now with dosing options up to a maximum of 25 mg once daily. This expanded dosing offers a non-injectable alternative for individuals seeking the benefits of GLP-1–based therapy for weight management, while maintaining meaningful efficacy.
As with other oral semaglutide formulations, administration technique is critical—it should be taken on an empty stomach with a small amount of water, with no food, beverages, or other medications for at least 30 minutes to optimize absorption.
Higher-dose oral therapy may help individuals who have reached a weight plateau or who require more intensive pharmacologic support, aligning with evolving treatment strategies that prioritize person-centered care and individualized therapy.
As always, it is important to provide guidance on gradual dose escalation and management of gastrointestinal side effects, ensuring individuals are supported every step of the way.
Rybelsus Rebranded: Introducing Oral Ozempic
In an effort to streamline GLP-1 therapy across formulations, Rybelsus (oral semaglutide) 1.5 mg, 4 mg, and 9 mg doses, is being rebranded as Oral Ozempic. The original Rybelsus 3, 7, and 14 doses will eventually be phased out. This naming alignment reflects the same active molecule—semaglutide—used in injectable Ozempic and Wegovy, helping reduce confusion and reinforce class familiarity among individuals and providers.
As with prior oral semaglutide formulations, proper administration remains key: it should be taken on an empty stomach with a small amount of water, with no food, beverages, or other medications for at least 30 minutes to ensure optimal absorption.
This update represents another step toward clarifying and simplifying diabetes treatment options.
New Once Weekly Insulin – Who Might Benefit Most?
We have also updated our Insulin PocketCard to include the newly approved ultra-long-acting insulin icodec.
This once weekly insulin may be especially valuable for:
- People with type 2 diabetes who struggle with taking daily injections.
- Individuals experiencing treatment fatigue
- Those who would benefit from simplified regimens
- Re-engaging patients hesitant to start insulin
This is where your role as a healthcare professional becomes even more powerful—matching the right therapy to the right person.
Our Insulin PocketCard Now includes icodec insulin.
Final Thoughts
As healthcare professionals, staying current with these advancements allows us to:
- Provide evidence-based recommendations
- Support informed decision-making
- And most importantly, meet people where they are
Want to Stay Current on Innovations Like This?
Join us as we break down the latest in diabetes care, guidelines, and emerging therapies— you can bring confidence, clarity, and compassion to your clinical practice by joining our Virtual DiabetesEd Training Conference.
Virtual DiabetesEd Training Conference
Why Should I Attend?
Join national experts including Dr. Diana Isaacs (Cleveland Clinic), Beverly Thomassian (30+ years of experience), and Christine Craig for high-impact, virtual learning—no travel required.
✔ Learn from National Experts — Anywhere
Get the same expert-level instruction you’d receive in person, delivered live to your home or office.
✔ Interactive & Flexible
- Live Q&A and real-time case discussions
- Direct engagement with faculty
- Full session recordings with 1-year access if you can’t attend live
What's Included?
- 19.5 CEs from the 3-day interactive conference + 17+ bonus CEs from 11 on-demand courses. (30+ total CEs are AMA PRA Category 1™, ACPE, ANCC, CDR accredited)
- Less than $15 per credit!
- Expert-led sessions: ADA Standards, medications, insulin therapy, behavior change, CGM, medical nutrition therapy
- Interactive Q&A with expert faculty during live sessions
- 1-year access to all recordings that you can watch on your schedule
- Study material for CDCES and BC-ADM exam prep
Set Yourself Up With Certification Success
Get exam-ready with confidence.
Course credits through AMA PRA Category 1 Credits™, ACPE, ANCC, and CDR!
Full accreditation details are available on the registration page
Our CDCES Boot Camp Online Prep Bundle is a comprehensive, high-impact program built specifically for healthcare professionals preparing for the Certified Diabetes Care and Education Specialist (CDCES) exam who want to level up their clinical knowledge and skills.
This evidence-based study bundle is a comprehensive BC-ADM Boot Camp designed for advanced-level healthcare professionals preparing for the Board Certified in Advanced Diabetes Management (BC-ADM) exam and will also provide you with state-of-the-art information to level up your clinical practice.
Hear What Our Community Has to Say
